Consortium to ‘Build Better Mice’

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 3
Volume 9
Issue 3

BETHESDA, Md-Seeking better mice for research, the National Cancer Institute has funded the Mouse Models of Human Cancer Consortium, which will consist of 19 new research groups involving investigators at 30 US institutions. The teams will seek to create models that duplicate the ways human cancers develop, progress, and respond to therapies or preventive agents.

BETHESDA, Md—Seeking better mice for research, the National Cancer Institute has funded the Mouse Models of Human Cancer Consortium, which will consist of 19 new research groups involving investigators at 30 US institutions. The teams will seek to create models that duplicate the ways human cancers develop, progress, and respond to therapies or preventive agents.

NCI expects the mouse models to aid in the discovery of new cancer-related genes and the pathways through which such genes exert their influence. The models eventually will be used to test experimental diagnostic and therapeutic techniques. Terry Van Dyke, PhD, of the University of North Carolina at Chapel Hill, and Tyler Jacks, PhD, of MIT, serve as the consortium's co-leaders.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.